期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

老老年冠心病患者强化降脂的疗效及安全性

下载PDF
导出
摘要 目的使用辛伐他汀对老老年（≧75 岁）冠心病患者行强化降脂治疗,观察其疗效及安全性.方法：选择临床确诊为冠心病的老老年患者共94 例,随机分为20mg 组和40mg 组,每晚8 时服药1 次,治疗前检测血脂、肝功能、及肌酸磷酸激酶（CK）.治疗后 1 个月、3 个月复查上述指标,并随访3 个月内的不良反应及心脏事件的发生情况.结果：（1）两组服药后第1 个月、3 个月的血脂较治疗前相比均有明显下降,其中40mg 剂量组在降低血脂及减少心血管事件发生率方面均明显优于20mg剂量组,两者结果有统计学差异.（2） 两组均无严重不良反应.结论：对于老老年冠心病患者应用辛伐他汀强化治疗可明显降低血脂,减少心脏事件的发生,且40mg 作用明显优于20mg.
作者 徐崇利 韦伟 严建军
机构地区 南京医科大学附属江宁医院心内科
出处 《河南中医》 2014年第B11期169-170,共2页 Henan Traditional Chinese Medicine
关键词 冠心病 辛伐他汀 强化降脂 老老年
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献7

  • 1Nomenclature and criteria for diagnosis of ischemic heart disease. Report of t heJoint International Society and Federation of Cardiology/ World Health Organization taskforce on standardization of clinical nomenclature[J].J Circulation,1979,59:607.
  • 2Heart Protection Study Collaborative Group.M RC/BHF Heart Protection Studyof cholestero llowering with simvastation in 5963 People with diabetes: a randomizedplacebo controlled trial [J]. lancet,2003,361:2005 2016.
  • 3熊全庚,范木林,郭跃华.早期强化辛伐他汀治疗急性冠状动脉综合征的研究[J].临床心血管病杂志,2004,20(12):710-712. 被引量：25
  • 4LaRosa JC, Grundy SM, Waters DD, etal Treating to New Targets(TNT)Investigators Intensive lipid lowering with atorvastatin in patients with stable coronarydisease[J].N Engl Med,2005;352(14):1425 35.
  • 5Expert panel on Detection Evaluation and Treatment of High blood cholesterol inAdults.Executive Summary of the Third Report of the Nat -ional cholesterol EducationProgram(N CEP) Expert pane/on Detection,Evaluation,and Treatment of High Bloodcholesterol in Adult(ATPⅢ).JAM A,2001,19:2486 2497.
  • 6姜一农.他汀类药物调脂外的其他有益的心血管作用[J].医师进修杂志,2001,24(12):12-13. 被引量：22
  • 7仝其广,胡大一.他汀类药物的安全性问题[J].中国实用内科杂志,2007,27(9):655-657. 被引量：64

二级参考文献20

  • 1Dupuis J, Tardif J C, Cernacek P, et al. Theroux cholesterol reduction rapidly improves endothelial function of the RECIFE (Reduction of cholesterol in ische-mial and function of the endothelium) trial. Circulation,1999,99: 3227- 3233.
  • 2The Long-term Intervention with Pravastatin in Ischaemic Disease(LIPID) study group. Prevention of cardiovascular events and a broad range of initial cholesterol levels. N EnglJ Med, 1998,339:1349-1357.
  • 3Pederson J R, Olsson A G, Faergeman V, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 1998,97:1453-1460.
  • 4FlakerG C, Warnica J W, Sacks F M,et al. For the Cholesterol and Recurrent Event(CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol, 1999,34:106- 112.
  • 5Schwartz G G, Olsson A G, Ezekowitz M D, et al.Effects of atorvastatin on early recurrent ische mic events in acute coronary syndrome. The MIRACL study: A randomized controlled trial. JAMA, 2001,285:1711-1718.
  • 6Maron D J, Fazio S, Linton M F. Current perspectives on statins. Circulation, 2000,101: 207- 213.
  • 7Bustos C, Hernandez-Presa M A, Ortego M, et al.HMG-GoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998,32:2057-2064.
  • 8Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthasc mRNA stability by Rho GTPase. J Biol Chem, 1998,273:24266-24271.
  • 9Williams J K, Sukova G K, Herrington D M, et al.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol, 1998,31: 684- 691.
  • 10MUECK A O,SEEGER H,WALLWIENER D.Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules[].Experimental and Clinical Endocrinology.2001

共引文献107

河南中医
2014年 第B11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部